Plasma p-tau217 was the strongest individual biomarker for predicting progression to Alzheimer's disease dementia in patients ...
The progression from mild cognitive impairment (MCI) to more severe neurocognitive disorders presents both a clinical challenge and an opportunity for early intervention. Predictive models have ...
Parkinson’s disease is characterised not only by motor impairments but also by a spectrum of cognitive changes that may progress from subtle executive dysfunction to dementia. Early and accurate ...